106 results about "Peptide nucleic acid" patented technology

The invention discloses a PNA-based pre-targeting probe as well as a preparation method and application thereof. The pre-targeting probe based on the PNA comprises a pre-targeting receptor probe PNA-EB-RGD and a ligand probe cPNA labeled by radionuclide, in the PNA-EB-RGD, the PNA is peptide nucleic acid, the EB is Evans blue, and the RGD is RGD peptide; the cPNA is a complementary sequence of the PNA. The PNA-based pre-targeting probe provided by the invention can reduce systemic circulation radiation exposure, obviously reduce blood toxicity and slow down tumor growth.

The invention discloses a polypeptide-nucleic acid tetrahedron compound as well as a preparation method and application thereof. The compound comprises a nucleic acid tetrahedron and polypeptide, wherein the polypeptide is nonapeptide-1 with an amino acid sequence as shown in SEQ ID NO: 13; the nucleic acid tetrahedron is formed by self-assembly of four single-stranded DNAs with the same length. According to the compound, the transdermal function of nucleic acid tetrahedron capable of inhibiting melanogenesis and the melanocyte targeting function of nonapeptide-1 are combined, so that the TDN-NA-1 compound has the melanocyte targeting property while having the autonomous transdermal ability, and the blackness inhibiting effects of the nucleic acid tetrahedron and the nonapeptide-1 are combined, so that the effect of inhibiting melanogenesis is achieved. Therefore, the whitening composition has a stronger capability of inhibiting melanin generation, so that the purpose of precise whitening is achieved, and the whitening composition has a wide application prospect in the field of cosmetics.

Compositions comprising a first polypeptide comprising a first fragment of an N-terminal extracellular domain of TSHR or an analog or derivative thereof and a dimerization domain and a second polypeptide comprising a second fragment of an N-terminal extracellular domain of TSHR or an analog or derivative thereof and a dimerization domain are provided. Polypeptides comprising fragments of an N-terminal extracellular domain of TSHR comprising at least one mutation that increases solubility, decreases aggregation or both are also provided. Pharmaceutical compositions comprising the composition, polypeptide, nucleic acid systems and molecules encoding the polypeptides of the composition and invention and methods of treatment and determining suitability for treatment using the compositions or polypeptides; as well as methods of producing the compositions or proteins are also provided.

The invention discloses a combination of blocking agents for detecting drug resistance of mycobacterium tuberculosis. The combination comprises a first peptide nucleic acid blocking agent, a second peptide nucleic acid blocking agent, a third peptide nucleic acid blocking agent and a fourth peptide nucleic acid blocking agent. The first peptide nucleic acid blocker covers codons 511 and 513 of the rpoB gene. The second peptide nucleic acid blocker covers the codon 516 of the rpoB gene. And the third peptide nucleic acid blocking agent covers the codon 526 of the rpoB gene. And the fourth peptide nucleic acid blocking agent covers codons 531 and 533 of the rpoB gene. The respective sequences of the first peptide nucleic acid blocker, the second peptide nucleic acid blocker, the third peptide nucleic acid blocker, and the fourth peptide nucleic acid blocker match the wild type of the corresponding sequence of the rpoB gene. The invention also provides a kit and a method for detecting the drug resistance of mycobacterium tuberculosis.

Use of a bitter melon exosome and an oral medicament prepared therefrom. The bitter melon exosome obtained from the bitter melon juice can be used for preparing a pharmaceutical formulation embedding a protein, a polypeptide, a small molecule peptide, a nucleic acid, or a small molecule compound. The compositions of the oral medicament of the present invention comprise the bitter melon exosome and an active pharmaceutical ingredient encapsulated in the bitter melon exosome. The bitter melon exosome is suitable for preparing a drug that is easily damaged by the gastrointestinal tract and is mostly administered by means of an injection route into an oral agent, and the oral agent can produce a similar therapeutic effect to that of the injection administration route by oral administration, and is convenient to use. The extraction method for the bitter melon exosome is simple and has a low cost. Moreover, the bitter melon exosome has no immunogenicity, has relatively high biocompatibility and biosafety, and has relatively strong tolerance to gastric acid and digestive tract proteolytic enzymes, and intestinal barrier permeability.

The invention relates to a primer-probe set, comprising a forward primer having the nucleotide sequence of SEQ ID NO:1 and a reverse primer having the nucleotide sequence of SEQ ID NO:2, and a peptide nucleic acid (PNA) probe having the sequence of HEX-OO-(SEQ ID NO:3)-Lysine-BHQ1, which are used for differentiating the Peste des Petits Ruminants (PPR) virus vaccine and field strains and for preventing false positive results arising from the PPR vaccine, as well as to their operating temperatures. Said primer-probe set can differentiate between the vaccine strain containing the nucleotide sequence of SEQ ID NO:4 and the field strain containing the nucleotide sequence of SEQ ID NO:5. Thus, by means of said primer-probe set, false positive results arising from the PPR vaccine are prevented, and accordingly, unnecessary quarantine measures are also avoided.

This invention discloses nucleic acid aptamers that specifically bind to the OmpK36 protein and their applications. Through analysis and screening, aptamers APT-1 and APT-2 that specifically bind to the OmpK36 protein were obtained. Nucleic acid aptamer APT-1 can specifically bind to outer membrane polypeptides, while nucleic acid aptamer APT-2 can specifically bind to polypeptides specific to Klebsiella pneumoniae. Both can bind to the OmpK36 protein to form a complex structure, which can be used for the specific detection of Klebsiella pneumoniae, providing convenience for clinical detection, diagnosis and treatment, and exclusion detection of specific pathogens in SPF animals.

The invention discloses a conservative B cell epitope peptide of goose parvovirus VP3 protein, a nucleic acid molecule, a recombinant vector and application thereof. Conservative B cell epitope EW12 is inserted into F18 Escherichia coli Fod fimbriae, inert carrier bacteria S9H are introduced, recombinant bacteria capable of functionally exhibiting and expressing the EW12 conservative B cell epitope on the surface of the bacteria are obtained, the recombinant bacteria can specifically generate specific binding reaction with gosling plague egg yolk antibody and gosling plague vaccine immune serum, and the gosling plague egg yolk antibody and the gosling plague vaccine immune serum can be specifically combined with the gosling plague egg yolk antibody and the gosling plague vaccine immune serum. The method has the advantages that macroscopic agglutination particles are generated, cross agglutination reaction with other pathogen positive serum and healthy goose serum is avoided, the method is good in sensitivity, and the specific antibody can be detected in the 5th day after immunization at the earliest. A plate agglutination test directly mediated by the goose parvovirus VP3 protein conservative B cell epitope peptide EW12 has the advantages of specificity, sensitivity, convenience in operation and suitability for on-site large-scale rapid detection, and is expected to provide a new technical means for diagnosis, prevention and control and purification of GPV infection.

Herpesviridae glycoprotein B (gB) polypeptides comprising a modified ectodomain is stabilized in the prefusion state, enabling development of inhibitors and vaccines directed against these viral pathogens. Modifications to DI, DII, and DV subdomains are important to stabilization of gB in the prefusion state, and additional modifications result in a further improved stabilization of gB in the prefusion state. The gB can be derived from an Epstein Barr Virus (EBV), a Human Cytomegalovirus (CMV), a Human Herpesvirus 6 (HHV6), a Herpes Simplex Virus 1 (HSV1), or a Varicella Zoster Virus (VZV). Polypeptides, nucleic acid constructs, compositions, and methods of using same to elicit an immune response are described.

The present invention provides a method for screening for a candidate peptide capable of binding to a target molecule, the method including the steps of: (1) preparing a plurality of nucleic acid display libraries containing a barcoded peptide-nucleic acid complex, wherein the barcoded peptide-nucleic acid complex contains a nucleic acid moiety and a peptide moiety, the nucleic acid moiety contains a barcode sequence and a nucleic acid sequence encoding the peptide, and the plurality of nucleic acid display libraries are nucleic acid display libraries, each of which is independently produced by translation using a cell-free translation system; (2) mixing the plurality of nucleic acid display libraries to prepare a mixed nucleic acid display library; (3) bringing the mixed nucleic acid display library into contact with the target molecule; and (4) amplifying a nucleic acid corresponding to the nucleic acid moiety of the barcoded peptide-nucleic acid complex bound to the target molecule, using a barcode primer.

This invention discloses a cyclic lipopeptide delivery system, comprising a cyclic lipopeptide carrier and nucleic acid; the head of the cyclic lipopeptide carrier is composed of heptapeptides R1R2R2R3R4R2R2 linked together by amide bonds to form a ring, and the hydrophobic tail of the cyclic lipopeptide carrier is composed of a fatty acid with a carbon chain length of 6-44 forming an ester bond with the hydroxyl group on the head amino acid R3, with the following general structural formula: where R1 is a basic amino acid, including one of histidine (His), lysine (Lys), or arginine (Arg); R2 is a hydrophobic amino acid, including one of leucine (Leu), isoleucine (Ile), or valine (Val); R3 is a hydrophilic amino acid, including one of tyrosine (Tyr), serine (Ser), or threonine (Thr); R4 is one of glutamate (Glu) or glutamine (Gln); n is an integer from 5 to 43; the cyclic lipopeptide carrier encapsulates the nucleic acid drug to form cyclic lipopeptide-nucleic acid nanoparticles.

The present application relates to (i) a variant adeno-associated virus (AAV) capsid polypeptide comprising a peptide insertion in the variable region IV or in the variable region VIII relative to a wild-type AAV capsid polypeptide, wherein the peptide insertion comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:1-29 or an amino acid sequence having at least 70% sequence identity thereto, (ii) an isolated nucleic acid encoding the aforementioned variant polypeptide, (iii) a recombinant polynucleotide comprising the aforementioned nucleic acid, and (iv) an isolated cell comprising the aforementioned polypeptide, nucleic acid or recombinant polynucleotide. The present application further relates to (v) an adeno-associated virus (AAV) vector comprising the aforementioned variant polypeptide, (vi) a pharmaceutical composition comprising the aforementioned AAV vector as well as (vii) the use of the aforementioned vector or pharmaceutical composition in preventing or treating an ocular disease. Finally, the present application relates to (viii) a method of delivering a heterologous nucleic acid to a retinal cell and (ix) a method of delivering a heterologous nucleic acid to the eye of a subject.

This invention relates to a polypeptide for gene delivery, a polypeptide / nucleic acid molecular complex prepared therefrom, and its applications. The polypeptide of this application has the structure shown in Formula I, wherein Formula I contains an immune cell targeting group represented by Y. The polypeptide developed in this application, as a gene delivery carrier, has a highly efficient nucleic acid loading capacity. Furthermore, it exhibits high delivery efficiency to immune cells both in vitro and in vivo, thus showing broad application prospects in the immune cell-targeted delivery of genes.

Provided are compositions comprising: a first polypeptide comprising a first fragment of an extracellular domain of ITGA2B or ITGB3, or an analog or derivative thereof, and a dimerization domain; and a second polypeptide comprising a second fragment of the extracellular domain of ITGA2B or ITGB3, or an analog or derivative thereof, and a dimerization domain. Also provided are polypeptides comprising a fragment of an extracellular domain of ITGA2B or ITGB3. Also provided is a pharmaceutical composition comprising the composition, a polypeptide; nucleic acid systems and molecules encoding the polypeptides of the compositions of the invention; and methods of treating and determining therapeutic suitability using the compositions or polypeptides; and methods of producing the compositions or proteins.

Provided herein are D domain-containing polypeptides that specifically bind to a target of interest, such as nucleic acids encoding the D domain-containing polypeptides, vectors containing the nucleic acids, and host cells containing the nucleic acids and vectors. Also provided herein are methods for producing and using D domain-containing polypeptides, nucleic acids, vectors, and host cells, for example, but not limited to, in diagnostic and therapeutic applications. Also provided herein are multifunctional chimeric antigen receptor (CAR)-based compositions and adapters, and their use in methods for directing an immune response against target cells. In some embodiments, the method includes the use of CAR-expressing cells in combination with an adapter. The adapter confers the ability to modulate, alter, and / or direct the cell-mediated immune response of the CAR-expressing cells in vitro and in vivo.

The invention related to the field of genetic engineering tools, methods and techniques for gene or genome editing. Specifically, the invention concerns isolated polypeptides having nuclease activity, host cells and expression vectors comprising nucleic acids encoding said polypeptides as well as methods of cleaving and editing target nucleic acids in a sequence-specific matter. The poly peptides, nucleic acids, expression vectors, host cells and methods of the present invention have application in many fields of biotechnology, including, for example, synthetic biology and gene therapy.

It provides a complex for target protein degradation. [Solution] The present invention relates to a novel compound-peptide nucleic acid-aptamer complex for targeted protein degradation and its applications. The complex is manufactured by binding a novel compound to a peptide nucleic acid and introducing an aptamer that can bind complementaryly to the peptide nucleic acid. It has been confirmed to have the effect of targeting and degrading intracellular target proteins such as Tau, nucleolin, and eIF4E, and can be usefully utilized in related industries.

Described are various embodiments of anti-cancer polypeptides, nucleic acid constructs. and methods of using same, particularly for the expression of protein comprising three thrombospondin-1 type 1 repeats (3TSR), as well as pharmaceutical compositions comprising any of the disclosed polypeptides or nucleic acid constructs for the treatment of solid tumor cancers such as ovarian cancer or pancreatic cancer.

Disclosed herein include systems, methods, compositions, and kits for prevention of antibody oligonucleotide extension. There are provided, in some embodiments, blocking oligonucleotides. In some embodiments, the blocking oligonucleotide comprises a binding region capable of hybridizing barcoding oligonucleotides to form a protected duplex. The blocking oligonucleotide can be a locked nucleic acid (LNA), a peptide nucleic acid (PNA), a DNA, an LNA / PNA chimera, an LNA / DNA chimera, or a PNA / DNA chimera. In some embodiments, the 3′ end of a blocking oligonucleotide is incapable of being extended by a reverse transcriptase or a polymerase. In some embodiments, the blocking oligonucleotide of a protected duplex is incapable of being removed by the strand displacement activity of a reverse transcriptase or a polymerase.

The present specification relates to compositions, devices, apparatus, methods, kits and systems for sample preparation (e.g., separation, reduction or removal of small molecules from biomolecules in a sample). Exemplary small molecules that can be separated, reduced or removed have a molecular weight range of <2000 Da. and may include, but are not limited to, dyes, biotin, affinity tags, crosslinkers, reducing agents, labels, nanoparticles, radioactive ligands, mass tags, unreacted molecules and combinations, intermediates and derivatives of the foregoing. Exemplary biomolecules present in a sample, include but are not limited to, proteins, glycoproteins, antibodies, peptides, nucleic acids, polysaccharides, carbohydrates and lipids. Methods, compositions, kits, devices, apparatus and systems of the disclosure may advantageously provide superior separation of small molecule contaminants and additionally reduce time and expenses related to separation of small molecules from larger biomolecules in samples. Biomolecules separated as set forth herein are amenable to better downstream processing.

This invention belongs to the field of nucleic acid aptamer technology. This invention provides a high-affinity and specific phalloidin nucleic acid aptamer and its applications. The base sequence of the high-affinity and specific phalloidin nucleic acid aptamer is shown in SEQ.ID.NO.1. The nucleic acid aptamer obtained by this invention exhibits strong specificity for phalloidin; after detection by graphene oxide fluorescence quenching, the measured fluorescence intensity reaches 867.6 (au), while its effects on other toxins and blank controls are not significant. Furthermore, it has high affinity for phalloidin, with a Kd value of 240 nM (0.203 ng / Kg). After 5' end FAM fluorescent labeling, the nucleic acid aptamer obtained by this invention can achieve visual detection of phalloidin under ultraviolet transmission irradiation.

The application discloses a method for detecting thyroid cancer driving gene mutations based on multiplex fluorescence PCR, and belongs to the technical field of molecular biology detection. The method simultaneously detects nine mutation sites, namely BRAF V600E, NRAS Q61R, NRAS Q61K, HRAS Q61R, HRAS Q61K, KRAS G12V, KRAS G12D, TERT C228T and TERT C250T in a single tube reaction. The method enhances the distinguishing ability of wild type and mutant types by using a locked nucleic acid modified allele-specific primer, suppresses wild type amplification by using a peptide nucleic acid clamp, introduces a competitive internal reference probe to correct amplification efficiency difference, and reduces the sample usage to one fifth of that of a traditional multi-tube scheme. The mutation detection lower limit reaches 0.5% allele frequency, and the total time consumption is not more than 2.5 h.

The application belongs to the field of biology, and discloses a method for high-throughput screening of viral CTL epitopes based on immunopeptidomics, which comprises the following steps: transfecting mammalian cells with eukaryotic expression plasmids having MHC I molecules in series with the alpha chain and the beta2m chain to establish a mammalian cell line expressing animal MHC I molecules; using a virus to infect the mammalian cell line expressing MHC I molecules to prepare MHC I-peptide complexes; and obtaining antigen peptides existing in the MHC I-peptide complexes. The method takes chicken MHC I allele BF2*1901 molecules as the research object, takes H9N2 subtype avian influenza virus as the model virus, comprehensively characterizes chicken MHC I restricted H9N2 antigen peptide groups, and identifies immunodominant CTL epitope immunity, and is suitable for CTL epitope screening of different chicken MHC I molecules and different subtypes of avian influenza viruses, provides a fast, efficient and economical technical means for studying the specific binding of chicken MHC I molecules and antigen peptides, provides a favorable reference for T cell epitope screening of major animal pathogens, and provides a scientific basis for poultry disease-resistant breeding, development of new vaccines and immune evaluation strategies. Meanwhile, the application also discloses restricted epitope peptides, nucleic acid molecules and applications.

Provided herein are D domain containing polypeptides that specifically bind targets of interest, as are nucleic acids encoding the D domain containing polypeptides, vectors containing the nucleic acids and host cells containing the nucleic acids and vectors. Also provided herein are methods of making and using the D domain containing polypeptides, nucleic acids, vectors and host cells, for example, but not limited to, in diagnostic and therapeutic applications. Also provided herein are multi-functional chimeric antigen receptor (CAR)-based compositions and Adapters and their use in methods of directing immune responses to target cells. In some embodiments, the methods include the use of a CAR expressing cell in combination with an Adapter. The Adapter confers the ability to modulate, alter, and / or direct CAR expressing cell-mediated immune response in vitro and in vivo.

The present application relates to a kind of polypeptide, nucleic acid construct and pharmaceutical composition for treating cancer, the amino acid sequence of polypeptide is RRVCVHFHFSLSLR.Compared with prior art, the polypeptide of the present application can significantly inhibit cancer cell proliferation, can be used for further depth development to inhibit tumor cell growth and antitumor drug, provides the biological active lead molecule with extremely commercial value for the treatment of cancer.

Provided are a binary complex containing a chaperone molecule and the use thereof in polypeptide sequencing. The binary complex comprises a chaperone molecule and a polypeptide to be detected that are covalently linked, wherein the chaperone molecule is selected from any one or more of the following: PEG, a spacer, a deoxyribose phosphate, a ribose phosphate, a nucleotide, a deoxynucleotide, a peptide nucleic acid or a locked nucleotide; the number of constituent units of the chaperone molecule is ≥1; and the number of amino acids of said polypeptide is ≥2. The above development and use are conducive to improving the resolution of nanopore polypeptide sequencing, and are of great significance for the advancement of nanopore polypeptide sequencing technology.

Influenza vaccines comprising a plurality of isolated polypeptides are described, as well as influenza vaccines comprising nucleic acid encoding the aforementioned polypeptides. Polypeptides, nucleic acid molecules, vectors, cells, pharmaceutical compositions, and 5 mRNAs are described, and their use as vaccines against viruses of the influenza virus family, and methods of treatment. The vaccines comprising encoding nucleic acid comprise one or more subunits comprising the encoding nucleic acid sequence.

This application relates to modified influenza A hemagglutinin polypeptides nucleic acids, such as messenger ribonucleic acids (mRNAs), encoding the same, as well as compositions comprising the same, vaccines comprising the same, and methods of using the same, such as in the prevention and / or treatment of diseases or conditions caused by influenza A viruses.

Provided is a composition for promoting migration of a target substance to the central nervous system, the composition containing a substance having an inhibitory activity against sphingomyelin synthase 1 (SMS1). Examples of the target substance include a compound, a peptide, a nucleic acid, a protein, an antibody, and a nucleic acid-containing vector, which are useful for preventing or treating central nervous system diseases.